1st Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Reform, H.R. 9 Innovation Act, S. 632 The STRONG Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 9 (114th), S. 632 (114th)

Trade (domestic/foreign) TRD

Trans Pacific Partnership (TPP), Trade Promotion Authority (TPA), General trade issues

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NAWEL LILLIAN ROJKJAER —
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Corporate Tax Reform, Administration's Tax Reform and 2016 Budget Proposals; Proposals to reform domestic and international tax structures

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0919-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics Implementations of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act (GDUFA) Generic drug pricing issues, Medicare Part D program and Generic Drugs House Energy & Commerce Committee 21st Century Cures Discussion document, Senate Report "Innovation for Healthier Americans" Drug Supply Chain Security Act implementation of pharmaceutical distribution REMs program, FAST Generics Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

PEPFAR, President's Emergency Plan for AIDS Relief funding, Global Fund funding, Generic Drug, Biosimilar User Fees, FY 2016 Budget, FY 2016 House and Senate Appropriations, FDA Safety Over Sequestration Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
NIMISH SHAH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —
MYLAN NV United Kingdom United Kingdom 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.